Hematopoiesis News 9.42 October 23, 2018 | |
| |
TOP STORYLILRB4 Signaling in Leukemia Cells Mediates T Cell Suppression and Tumor Infiltration Scientists showed that LILRB4, an immunoreceptor tyrosine-based inhibition motif-containing receptor and a marker of monocytic leukemia, supported tumor cell infiltration into tissues and suppressed T cell activity via a signaling pathway that involved APOE, LILRB4, SHP-2, uPAR and ARG1 in acute myeloid leukemia cells. [Nature] Abstract | Press Release | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Lin−CCR2+ Hematopoietic Stem and Progenitor Cells Overcome Resistance to PD-1 Blockade Researchers found that bone marrow-derived, lineage-negative hematopoietic stem and progenitor cells that expressed C-C chemokine receptor type 2 (CCR2+) reversed treatment resistance and sensitized mice to curative immunotherapy. [Nat Commun] Full Article | Press Release Long Non-Coding RNA-Dependent Mechanism to Regulate Heme Biosynthesis and Erythrocyte Development Investigators discovered that UCA1 expression was dynamically regulated during human erythroid maturation, with a maximal expression in proerythroblasts. UCA1 depletion predominantly impaired heme biosynthesis and arrested erythroid differentiation at the proerythroblast stage. [Nat Commun] Full Article In mice subjected to 12 weeks of chronic renal failure (CRF), bone marrow hematopoietic stem cell (HSC) frequencies were decreased and transplantation of bone marrow cells from CRF donors showed a decrease in long-term HSC repopulation compared to controls. [Sci Rep] Full Article Researchers used CD34+ hematopoietic stem cells in bone marrow from patients with myelodysplastic syndrome. They found that early B cell factor 1 (EBF1) had a positive effect on the promotion of bone marrow CD34+ cell proliferation as well as its migration, but inhibited the apoptosis of cells. [J Cell Biochem] Abstract The authors investigated the regulation mechanism of promyelocytic leukemia (PML)/retinoic acid receptor-alpha (RARα) to MYB proto-oncogene and the role of this regulation on the proliferation and differentiation of acute promyelocytic leukemia cells. Functionally, PML/RARα increased cell proliferation and blocked differentiation through activating MYB expression. [J Cell Biochem] Abstract Scientists confirmed that activation of EPHB2 on CD34+ hematopoietic stem/progenitor cells, via EFNB1-Fc stimulation, enhanced myeloid/erythroid colony formation, whereas functional blocking of either EPHB1 or EPHB2 inhibited the maintenance of long-term culture initiating-cells. [Exp Hematol] Full Article Thirty seven cell lines were established from human bone marrow cells from a single donor. The time required for the establishment of each cell line varied greatly from 46 to 246 days. Of these lines, five were selected and their characteristics were analyzed. [Exp Hematol] Abstract CLINICAL RESEARCHSotatercept was effective and well tolerated in patients with β-thalassemia. Most non-transfusion-dependent β-thalassemia patients treated with higher doses achieved sustained increases in hemoglobin level. [Haematologica] Full Article Patients in complete remission were randomly assigned to receive either the FBA or the BuCy2 regimen. The difference in 100-day transplant-related mortality (TRM) was not statistically significant between the two arms, as were the cumulative incidences of relapse, TRM, overall survival and event-free survival at 3 years. [Bone Marrow Transplant] Abstract Prognostic Role of DOK Family Adapters in Acute Myeloid Leukemia In patients who underwent allogeneic hematopoietic stem cell transplantation all downstream of tyrosine kinase (DOK) members had no impact on EFS and OS. Multivariate analysis confirmed that high DOK5 expression was an independent risk factor for EFS and OS in untransplanted patients. [Cancer Gene Ther] Abstract Subscribe to one of our other 19 science newsletters such as Cord Blood News & Cell Therapy News. | |
| |
REVIEWSPolycomb Complexes in Normal and Malignant Hematopoiesis Investigators present an overview of the role of polycomb group (PcG) proteins in normal and malignant hematopoiesis, focusing on the compositional complexity of PcG complexes, and they briefly discuss the ongoing clinical trials for drugs targeting these factors. [J Cell Biol] Abstract Osteogenic Niche in the Regulation of Normal Hematopoiesis and Leukemogenesis The authors discuss the signaling pathways that regulate osteogenic niche-hematopoietic stem and progenitor cells or osteogenic niche-leukemic stem/initiating cells interactions in the bone marrow as well as novel approaches for therapeutically targeting these interactions. [Haematologica] Full Article Visit our reviews page to see a complete list of reviews in the hematopoiesis research field. | |
| |
SCIENCE NEWSRocket Pharmaceuticals Presents Preclinical Data Rocket Pharmaceuticals, Inc. presented preclinical data from the company’s Leukocyte Adhesion Deficiency-I and Infantile Malignant Osteopetrosis lentiviral vector-based gene therapy programs. [Press release from Rocket Pharmaceuticals, Ltd. discussing research presented at the 2018 Annual Congress of the European Society of Gene and Cell Therapy, Lausanne] Press Release | |
| |
INDUSTRY NEWSOrgenesis Inc. announced it has entered into a collaboration agreement with Immugenyx, LLC. Immugenyx will collaborate with Orgenesis to further the development and commercialization of its advanced hematopoietic chimeras. [Orgenesis Inc.] Press Release Orgenesis Announces Collaboration with Hemogenyx to Develop Blood Stem Cell Replacement Product Orgenesis Inc. announced it has entered into a collaboration agreement with Hemogenyx Pharmaceuticals Plc to collaborate on the development and commercialization of Hemogenyx’s Human Postnatal Hemogenic Endothelial technology. [Orgenesis Inc.] Press Release Genmab A/S announced the study met its primary endpoint for Part 1 of the Phase III CASSIOPEIA study of daratumumab in combination with bortezomib, thalidomide and dexamethasone (VTD) versus VTD alone as frontline treatment for patients who are candidates for autologous stem cell transplant. [Genmab A/S] Press Release Cellect Announces Positive Clinical Results Cellect Biotechnology Ltd. announced further data from a Phase I/II study of its ApoGraft™ technology. With half of the patients planned for the study having finished first month follow up, all such patients have shown 100% engraftment with no procedure related adverse events reported. [Cellect Biotechnology Ltd. (PR Newswire Association LLC.)] Press Release $5 Million Grant to Expand Blood Cancer Therapy Options Using a new Specialized Center of Research grant from the Leukemia and Lymphoma Society, a team from Baylor College of Medicine and the Center for Cell and Gene Therapy at Baylor, Houston Methodist Hospital and Texas Children’s Hospital will work to develop more widely applicable targeted cellular therapies for leukemia and lymphoma. [Baylor College of Medicine] Press Release ASH Bridge Grant Program Funds Eight Promising Biomedical Research Projects The American Society of Hematology (ASH) announced the names of eight investigators who have each been awarded $150,000 through the ASH Bridge Grant Program. Designed to support promising hematology research, ASH Bridge Grants will ensure that innovative research continues at institutions across the country. [American Society of Hematology] Press Release | |
| |
POLICY NEWSNo PhDs Needed: How Citizen Science Is Transforming Research Projects that recruit the public are getting more ambitious and diverse, but the field faces some growing pains. Citizen science — active public involvement in scientific research — is growing bigger, more ambitious and more networked. [Nature News] Editorial Azar Is Empowering Anti-Fetal Tissue Research Ideologues at the Expense of Science Earlier this month, Alex Azar, secretary of the Department of Health and Human Services, visited South America, where he touted the work the United States has done to halt the spread of diseases in the region. But the same week Azar that was praising U.S.-driven health care successes abroad, he put the scientific advances of tomorrow at risk by prioritizing a far-right political ideology ahead of evidence and the health of the public. [STAT News] Editorial
| |
EVENTSNEW 11th American Association for Cancer Research (AACR) and Japanese Cancer Association (JCA) Joint Conference Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Faculty Positions – Hematology and Oncology (UC Davis) Postdoctoral Positions – Cell Fate Commitment in Hematopoiesis (The Wistar Institute) Postdoctoral Position or PhD Student – Bioinformatics in Leukemia (RWTH Aachen Medical School) Postdoctoral Fellowship – Translational Leukemia Research (Lund University) Postdoctoral Associate – Hematopoiesis and Leukemia (The Jackson Laboratory) Postdoctoral Fellow – Myelodysplasia and Acute Myeloid Leukemia (University of New South Wales) Postdoctoral Position – Stem Cells, Development and Cancer (Albert Einstein College of Medicine) Senior Scientist – CAR T-Cell Research (CELLECTIS Inc.) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Hematopoiesis News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|